Fatal and non-fatal cardiovascular events in a general population prescribed sibutramine in New Zealand: a prospective cohort study.
BACKGROUND
The cardiovascular safety of sibutramine is currently under review by medicines regulatory authorities worldwide after the SCOUT (Sibutramine Cardiovascular Outcome Trial) showed an increased risk of cardiovascular events in patients taking sibutramine. Further data regarding the cardiovascular safety of sibutramine in a general population are now required.


OBJECTIVE
To quantify the risk of fatal and non-fatal cardiovascular adverse events in a general population prescribed sibutramine in postmarketing use.


METHODS
Observational prospective cohort study of patients dispensed sibutramine during a 3-year period (2001-4) and followed up for at least 1 year after their last prescription. The study included record-linkage to national mortality datasets to identify fatal events.


METHODS
Postmarketing 'real-life' use of sibutramine in a general population in New Zealand.


METHODS
All New Zealand patients dispensed a prescription for sibutramine in a 3-year period (for whom a National Health Identification number could be validated). 15 686 patients were included in the record linkage study for fatal events. A subgroup of 9471 patients was followed up by intensive methods for non-fatal events.


METHODS
(i) Rate of death from all causes and from cardiovascular events; and (ii) rates of non-fatal cardiovascular adverse events.


RESULTS
Total exposure to sibutramine for 15 686 patients in the validated cohort was 5431 treatment-years. The rate of death from all causes in this cohort was 0.13 (95% CI 0.05, 0.27) per 100 treatment-years exposure. The rate of death from a cardiovascular event was 0.07 (95% CI 0.02, 0.19) per 100 treatment-years exposure. The most frequent non-fatal cardiovascular events in the intensively followed up cohort were hypertension, palpitations, hypotensive events and tachycardia.


CONCLUSIONS
Risk of death from a cardiovascular event in this general population of patients prescribed sibutramine was lower than has been reported in other overweight/obese populations. The results of this study suggest that further evaluation of the benefit-risk profile of sibutramine is now required.
Harrison-Woolrych
Mira
M
Intensive Medicines Monitoring Programme, Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand. mira.harrison-woolrych@otago.ac.nz
Ashton
Janelle
J
Herbison
Peter
P
D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems; D000368:Aged; D001067:Appetite Depressants / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000453:epidemiology* / Q000401:mortality; D015331:Cohort Studies; D003503:Cyclobutanes / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009026:Mortality / Q000639:trends; D009520:New Zealand / Q000453:epidemiology; D011446:Prospective Studies; D011795:Surveys and Questionnaires
D001067:Appetite Depressants; D003503:Cyclobutanes; C058254:sibutramine